Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$0.69 USD
-0.01 (-1.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.69 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Income Statements
Fiscal Year end for Atara Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 9 | 64 | 20 | 0 | 0 |
Cost Of Goods | 9 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 64 | 20 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 276 | 344 | 361 | 309 | 296 |
Income After Depreciation & Amortization | -276 | -281 | -340 | -309 | -296 |
Non-Operating Income | 5 | 52 | 0 | 2 | 5 |
Interest Expense | 5 | 0 | 0 | 0 | 0 |
Pretax Income | -276 | -228 | -340 | -307 | -291 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -276 | -228 | -340 | -307 | -291 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -276 | -228 | -340 | -307 | -291 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -270 | -274 | -329 | -300 | -290 |
Depreciation & Amortization (Cash Flow) | 6 | 7 | 11 | 9 | 6 |
Income After Depreciation & Amortization | -276 | -281 | -340 | -309 | -296 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 105.91 | 101.99 | 93.67 | 73.97 | 51.31 |
Diluted EPS Before Non-Recurring Items | -2.61 | -2.73 | -3.63 | -4.15 | -5.67 |
Diluted Net EPS (GAAP) | -2.61 | -2.24 | -3.63 | -4.15 | -5.67 |
Fiscal Year end for Atara Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 4.25 | 2.14 | 0.96 | 1.23 |
Cost Of Goods | NA | 3.16 | 2.62 | 2.90 | 0.22 |
Gross Profit | NA | 1.09 | -0.48 | -1.94 | 1.01 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 61.05 | 69.14 | 69.48 | 76.03 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -59.96 | -69.62 | -71.42 | -75.02 |
Non-Operating Income | NA | 0.70 | 1.19 | 1.69 | 1.61 |
Interest Expense | NA | 1.18 | 1.40 | 1.38 | 1.34 |
Pretax Income | NA | -60.44 | -69.82 | -71.11 | -74.75 |
Income Taxes | NA | 0.01 | -0.02 | 0.00 | 0.02 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -60.45 | -69.80 | -71.11 | -74.77 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -60.45 | -69.80 | -71.11 | -74.77 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 108.14 | 106.40 | 105.09 | 103.97 |
Diluted EPS Before Non-Recurring Items | NA | -0.56 | -0.66 | -0.68 | -0.72 |
Diluted Net EPS (GAAP) | NA | -0.55 | -0.66 | -0.68 | -0.72 |